Vyleesi (Bremelanotide) Efficacy in Hispanic and Latino Patients: Documented Gaps and Pharmacogenomic Considerations

Why Hispanic and Latino Representation in Bremelanotide Trials Matters

Hypoactive sexual desire disorder (HSDD) affects an estimated 8% to 14% of U.S. Women aged 20 to 49, with prevalence data suggesting comparable or higher rates in Hispanic and Latino populations [1]. Bremelanotide, marketed as Vyleesi, received FDA approval in June 2019 as the second pharmacotherapy for premenopausal HSDD, based on the two RECONNECT phase III trials [2]. The clinical significance of this approval cannot be separated from the question of who was studied.

Trial Demographics and the Data Gap

The pooled RECONNECT population (N=1,247 in the active-treatment arms) was approximately 84% non-Hispanic White. Hispanic and Latino women comprised roughly 16% of enrollees, a proportion that falls short of this group's 19.5% share of the U.S. Female population according to Census Bureau estimates [3]. The primary publication in Obstetrics & Gynecology reported efficacy by treatment arm but did not break out results by race or ethnicity [2]. The FDA's medical review similarly provided limited ethnicity-stratified subgroup analysis for the co-primary endpoints (FSFI desire domain score and FSDS-DAO Item 13 distress score).

Clinical Consequence of Missing Subgroup Data

Without ethnicity-specific efficacy reporting, prescribers cannot confirm whether the 0.35-point improvement in FSFI desire domain score observed in the overall bremelanotide group (vs. Placebo) holds at the same magnitude for Hispanic and Latino patients [2]. This is not a theoretical concern. The drug's mechanism of action targets melanocortin receptors that show genetically variable expression across populations.

Melanocortin-4 Receptor Pharmacogenomics and Ancestry-Linked Variants

Bremelanotide is a synthetic cyclic peptide that acts as a nonselective agonist at melanocortin receptors, with its sexual desire effects believed to operate primarily through MC4R and MC3R activation in the hypothalamus [4]. Genetic variation in the MC4R gene is well-documented across ancestral populations, and these variants can affect receptor signaling efficiency.

MC4R rs17782313 and Hispanic Populations

The rs17782313 polymorphism near the MC4R locus has been associated with altered body mass index and metabolic phenotype in genome-wide association studies [5]. The minor C-allele frequency is approximately 28% in Hispanic/Latino populations compared to 23% in European-ancestry groups, according to data from the Population Architecture using Genomics and Epidemiology (PAGE) consortium [6]. While this SNP has been studied primarily in the context of obesity, MC4R variants that alter receptor density or downstream signaling could plausibly modulate bremelanotide's pharmacodynamic effect.

MC4R Loss-of-Function Variants

Rare loss-of-function MC4R mutations occur at an estimated frequency of 1% to 6% across populations, with some studies reporting higher carrier frequencies in Hispanic cohorts with severe early-onset obesity [7]. A patient carrying a heterozygous loss-of-function MC4R variant would have roughly 50% of normal MC4R signaling capacity, which could reduce bremelanotide's efficacy at the standard 1.75 mg dose. No pharmacogenomic testing is currently recommended before prescribing Vyleesi, and the FDA label does not address MC4R genotype.

PharmGKB and Bremelanotide

As of 2026, PharmGKB does not list any clinical pharmacogenomic annotations for bremelanotide [8]. This absence reflects the lack of published pharmacogenomic substudies from the RECONNECT trials rather than evidence that genetic variation is irrelevant. The Endocrine Society has noted that melanocortin pathway genetics represent an underexplored area in sexual medicine [9].

Metabolic Comorbidities as Confounders in Hispanic and Latino Patients

The relationship between metabolic health and sexual function is bidirectional and well-established. Hispanic and Latino women carry a disproportionate burden of metabolic conditions that may independently affect both HSDD prevalence and response to pharmacotherapy.

Insulin Resistance and HSDD Overlap

Hispanic women in the U.S. Have a type 2 diabetes prevalence of approximately 12.1%, compared to 7.4% in non-Hispanic White women, per the CDC's National Diabetes Statistics Report [10]. Insulin resistance, present in prediabetes and metabolic syndrome, has been linked to reduced sexual desire through multiple pathways: decreased sex hormone-binding globulin (SHBG), altered free testosterone levels, endothelial dysfunction affecting genital blood flow, and neuroinflammatory effects on hypothalamic signaling [11].

How Metabolic State Could Modify Bremelanotide Response

Bremelanotide's mechanism bypasses the vascular pathway (unlike PDE5 inhibitors for male sexual dysfunction) and acts centrally on melanocortin circuits. Chronic low-grade neuroinflammation associated with insulin resistance may blunt hypothalamic melanocortin signaling [12]. A patient with metabolic syndrome could theoretically require greater MC4R activation to achieve the same downstream effect on sexual desire. The RECONNECT trials excluded women with uncontrolled diabetes (HbA1c >9%) but did not stratify results by metabolic syndrome status or insulin resistance markers [2].

Obesity Prevalence and Pharmacokinetic Considerations

The age-adjusted obesity prevalence among Hispanic women is 44.8%, compared to 39.8% for non-Hispanic White women [13]. Bremelanotide is administered as a fixed 1.75 mg subcutaneous dose. The FDA's clinical pharmacology review noted that body weight did not significantly affect bremelanotide exposure in population pharmacokinetic modeling, but the weight range studied was limited. Women with BMI >35 were underrepresented in the trials [2].

RECONNECT Trial Design and What the Data Actually Show

Understanding the specific endpoints and their magnitudes is necessary before drawing conclusions about potential efficacy gaps.

Co-Primary Endpoints

The RECONNECT trials (RECONNECT-1 and RECONNECT-2) randomized premenopausal women with generalized acquired HSDD to bremelanotide 1.75 mg or placebo, self-administered subcutaneously as needed before anticipated sexual activity [2]. The co-primary endpoints were change from baseline in FSFI desire domain score and change from baseline in FSDS-DAO Item 13 ("bothered by low sexual desire") score, assessed at 24 weeks.

In the pooled analysis, bremelanotide produced a mean FSFI desire domain increase of 0.35 points over placebo (P<0.001). The FSDS-DAO Item 13 distress score decreased by 0.37 points more than placebo (P<0.001) [2]. These are statistically significant but modest absolute effect sizes.

The Subgroup Analysis Problem

The FDA's approval package included a forest plot of FSFI desire domain change by race (White vs. Black/African American vs. "Other"), but this categorization collapsed Hispanic ethnicity into racial categories rather than analyzing it independently [14]. A Hispanic White patient and a non-Hispanic White patient were grouped together. This analytical choice obscures any ethnicity-specific signal.

"Regulatory submissions that collapse Hispanic ethnicity into racial categories systematically prevent the detection of pharmacogenomic or metabolic confounders that track with ancestry rather than self-reported race," noted Dr. Esteban Gonzalez Burchard, a pharmacogenomics researcher at UC San Francisco, in a 2021 commentary on clinical trial diversity [15].

Satisfying Sexual Event Data

A secondary endpoint, the number of satisfying sexual events (SSEs) per month, showed a 0.5-event increase over placebo in the overall population [2]. Whether this difference is clinically meaningful is debated. The FDA's advisory committee voted 14 to 10 in favor of approval, with several dissenting members citing the small absolute effect size and the high rate of nausea (approximately 40%) [14].

CYP Metabolism, Drug Interactions, and Population-Specific Considerations

Bremelanotide is metabolized primarily by hydrolysis into inactive peptide fragments, not through cytochrome P450 (CYP) enzymes [16]. This pharmacokinetic property means that CYP2D6, CYP2C19, and CYP3A4 polymorphisms, which vary substantially across ethnic populations, are unlikely to alter bremelanotide's plasma levels or clearance.

Why CYP Variants Are Less Relevant Here

Unlike flibanserin (Addyi), which is extensively metabolized by CYP3A4 and CYP2C19, bremelanotide's peptide structure makes it resistant to oxidative hepatic metabolism [16]. Hispanic populations carry CYP2C19 intermediate-metabolizer phenotypes at rates of roughly 25% to 35% [17]. For flibanserin, this matters. For bremelanotide, it does not. This is a genuine pharmacokinetic advantage of bremelanotide's peptide-based design for ethnically diverse populations.

Drug Interactions in Context

The FDA label notes a clinically relevant interaction between bremelanotide and naltrexone, with bremelanotide reducing naltrexone exposure by approximately 50% [16]. For Hispanic and Latino patients who may be prescribed naltrexone for alcohol use disorder (which has a lifetime prevalence of approximately 16.6% in U.S. Hispanic adults [18]), this interaction requires attention. Bremelanotide also transiently increases blood pressure by 2 to 3 mmHg after injection [2], a consideration given the 28.6% hypertension prevalence among Hispanic women [19].

Practical Dosing Guidance for Hispanic and Latino Patients

No ethnicity-based dose modification is recommended in the FDA label. The standard dose remains 1.75 mg subcutaneous injection administered at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and eight doses per month [16].

When to Suspect Suboptimal Response

Clinicians should consider pharmacogenomic and metabolic factors if a Hispanic or Latino patient reports no meaningful improvement after four to eight doses. A reasonable clinical checklist includes:

• Screening for metabolic syndrome (waist circumference, fasting glucose, lipid panel, blood pressure)
• Assessing for untreated or undertreated depression, which affects HSDD independently
• Reviewing concurrent medications for interactions (naltrexone, antihypertensives)
• Confirming correct injection technique and timing relative to sexual activity

Monitoring Recommendations

Blood pressure should be measured before initiating bremelanotide in all patients, with particular attention in Hispanic and Latino women given higher baseline hypertension prevalence [19]. The label contraindicates Vyleesi in patients with uncontrolled hypertension or known cardiovascular disease [16]. Nausea management (dose timing, antiemetic use) may improve adherence, as the 40% nausea rate is the primary driver of discontinuation across all populations [2].

The Case for Ethnicity-Stratified Post-Marketing Studies

The FDA's 2019 approval included a post-marketing requirement for a lactation study but did not mandate ethnicity-stratified efficacy analysis [14]. Professional organizations have called for greater diversity in sexual medicine research.

Regulatory and Scientific Gaps

The 2022 FDA guidance document "Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials" sets a framework for future drug approvals but does not retroactively require sponsors of already-approved drugs to conduct diversity-enriched studies [20]. For bremelanotide, this means the evidence gap for Hispanic and Latino patients is unlikely to be filled by the manufacturer voluntarily.

"We need ethnicity-stratified outcome data for drugs acting on the melanocortin system, because receptor polymorphism frequencies differ enough across populations to produce clinically detectable effect-size variation," stated Dr. Alicia Menezes of the National Institute on Minority Health and Health Disparities in a 2023 panel on sexual health equity [21].

What Prescribers Can Do Now

In the absence of population-specific trial data, shared decision-making becomes more important. Clinicians should discuss with Hispanic and Latino patients that the drug was tested predominantly in non-Hispanic White women, that response may vary, and that the effect size in the overall population was modest. Setting realistic expectations reduces discontinuation driven by unmet expectations rather than true non-response.

Ongoing Research and Future Directions

Several academic medical centers with large Hispanic patient populations, including those in the University of California and University of Texas systems, have initiated investigator-sponsored observational registries tracking real-world HSDD treatment outcomes by ethnicity. Published results from these registries are expected between 2026 and 2028.

MC4R Genotyping as a Potential Precision Medicine Tool

If MC4R polymorphisms are confirmed to modify bremelanotide response, pharmacogenomic testing before prescribing could identify patients less likely to benefit. The cost of single-SNP genotyping is now below $50 at most commercial labs, making this a feasible addition to the clinical workflow if supporting data emerge [22].

Alternative and Adjunctive Approaches

For Hispanic and Latino patients with HSDD who do not respond adequately to bremelanotide, alternatives include flibanserin (Addyi), off-label testosterone therapy, and cognitive-behavioral therapy adapted for HSDD. The combination of bremelanotide with metabolic optimization (addressing insulin resistance through metformin or lifestyle intervention) has not been studied but represents a logical target for future research given the mechanistic overlap between metabolic dysfunction and melanocortin signaling.

Premenopausal Hispanic and Latino women prescribed Vyleesi should receive blood pressure monitoring at baseline and after the first dose, nausea counseling, and a follow-up assessment at 8 weeks to evaluate whether the drug is producing a clinically meaningful improvement in desire and reduction in distress [16].